Evidence map›Paper›PMID 34106658›Full record

Observational studyMedicine2021

Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.

Hèctor Corominas, Ivan Castellví, César Diaz-Torné, Laia Matas, David de la Rosa, Maria Antònia Mangues, Patricia Moya, Virginia Pomar, Natividad Benito, Ester Moga and 3 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Hèctor CorominasServei de Reumatologia.
Ivan CastellvíServei de Reumatologia.
César Diaz-TornéServei de Reumatologia.
Laia MatasServei de Medicina Interna.
David de la RosaServei de Pneumologia.
Maria Antònia ManguesServei de Farmàcia Hospitalària.
Patricia MoyaServei de Reumatologia.
Virginia PomarUnitat de Malalties Infeccioses.
Natividad BenitoUnitat de Malalties Infeccioses.
Ester MogaServei Immunologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain.
Nerea Hernandez-de SosaServei de Medicina Interna.
Jordi CasademontServei de Medicina Interna.
Pere DomingoUnitat de Malalties Infeccioses.
Sociedad Española de Reumatología · ESSociedad Española de Medicina Interna · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractBlocking IL-6 pathways with sarilumab, a fully human anti-IL-6R antagonist may potentially curb the inflammatory storm of SARS-CoV2. In the present emergency scenario, we used "off-label" sarilumab in 5 elderly patients in life-threatening condition not candidates to further active measures. We suggest that sarilumab can modulate severe COVID-19-associated Cytokine Release Syndrome.

Indexed as

COVID-19 Drug TreatmentInterleukin-6 InhibitorsAgedAntibodies, Monoclonal, HumanizedAnti-Infective AgentsAzithromycinComorbidityCOVID-19Critical IllnessCytokine Release SyndromeHumansHydroxychloroquineMaleMiddle AgedRespiration, ArtificialRetrospective StudiesAntibodies, Monoclonal, HumanizedAnti-Infective AgentsAzithromycinHydroxychloroquineInterleukin-6 InhibitorsRNA, Viralsarilumab

Identifiers

PMID34106658
PMCPMC8133253
OpenAlexW3161862223

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.